INTRODUCTION TO BIOMARKERS - Flow Cytometry in Drug Discovery and Development - page 64

8. Sledge GW, Jr., Circulating tumor cells in breast cancer: blood will tell. Clin. Cancer Res.
2006;12:6321.
9. Di Costanzo F, Pinzani P, Orlando C, Gasperoni S, Vannini L, Mario PA. Circulating
tumour cells in colorectal cancer. Eur. J. Cancer Suppl. 2008;6(14):52-59.
10. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas MA, d'Assignies SM, Bergh J,
Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F,
Rutgers E, Sotiriou C, Cardoso F, Piccart JM. Validation and clinical utility of a 70-gene
prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst.
2006;98(17):1183-1192.
11. Flanagan BM, Dabbs JD, Brufsky MA, Beriwal S, Bhargava R. Histopathologic variables
predict Oncotype DX Recurrence Score. Mod. Pathol. 2008;21:1255-1261.
12. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment
selection. Nat. Rev. Cancer 2005;5:845-856.
13. Wu AHB, Shea E, Thuc Lu Q, Minyard J, Bui K, Hsu JC, Agee SJ, Todd J. Short- and long-
term cardiac troponin I analyte stability in plasma and serum from healthy volunteers
by use of an ultrasensitive, single-molecule counting assay. Clin. Chem. 2009;55:
2057-2059.
14. Ledger K, Agee SJ, Kasaian MT, Forlow SB, Durn BL, Minyard J, Lu QA, Todd J,
Vesterqvist O, Burczynski ME. Analytical validation of a highly sensitive microparticle-
based immunoassay for quantitation of IL-13 in human serum using the Erenna
immunoassay system. J. Immunol. Methods 2009;350:161-170.
15. Burczynski ME, Vesterqvist OE. Quantitative PCR assays in clinical drug development.
Eur. Pharm. Rev. 2006;5.
16. Kulasingam V, Diamonds PE. Strategies for discovering novel cancer biomarkers
through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008;5
(10):588-598.
17. Isler JA, Vesterqvist OE, Burczynski ME. Analytical validation of genotyping assays in the
biomarker laboratory. Pharmacogenomics 2007;8:353-368.
18. Hanash MS, Pitteri JS, Faca MV. Mining the plasma proteome for cancer biomarkers.
Nature 2008;452:571-579.
19. McPherson JD. Next-generation gap. Nat. Methods Suppl. 2009;6(11 Suppl.):S2-S5.
20. Philip R, Gutman SI, Chan MM. FDA perspective on validating proteomic biomarkers for
in vitro diagnostic use. Am. Drug Discov. 2008;3(6):30-33.
21. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S,Weinryb I,
Green M, Duan L, Rogers J, Millham R, O'Brien P, Sailstad J, Khan M, Ray C, Wagner J.
Fit-for-purpose method development and validation for successful biomarker

measurement. Pharm. Res. 2006;23:312-328.
22. Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. Annu.
Rev. Pharmacol. Toxicol. 2008;48:22.1-22.21.
23. Vesterqvist O, Park CH, Rutkowski JL. From biological measures to valid biomarker:
predicting success of novel therapeutics. Am. Drug Discov. 2008;3(3):56-59.
24. Vesterqvist O, Manning JA, Uderman H, Delaney C, Beierle F, Swanson BN, Liao W.
Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic
markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE)
activity in healthy men. Clin. Pharmacol. Ther. 1997;61:230 (abstract).